Welcome to the News Room

Pugatch Consilium unveiled at the Financial Times Latin America Healthcare & Life Sciences Summit in Sao Paulo Brazil the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Latin America Special Report. This Report is derived from the main 2017 BCI Survey, a global executive opinion survey and index that measures the relative attractiveness of economies to investment from biopharmaceutical research-based companies.

The Report deep-dives into ten Latin American countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Panama and Peru. ...

Pugatch Consilium has released the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Survey. An executive opinion survey, in 2017 the BCI polled business leaders and local general managers from the biopharmaceutical industry about the investment environment in 31 markets. The results are available in the linked report below.

The headline results of the 2017 BCI Survey include:

• The policy environment matters a great deal for biopharmaceutical investment decisions. Economies with policies supporting biopharmaceutical innovation and investment are much more likely to actually secure ...

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place.

A new blog post by Prof Meir Pugatch on PhRMA’s The Catalyst discusses these results and ...

Professor Meir Pugatch and Dr. David Torstensson are speaking today at the BIO international convention held in San Diego, CA. Sponsored by the Biotechnology Innovation Organization, the annual convention hosts more than 16,000 attendees from over 70 countries.

Yesterday Professor Pugatch participated in a high level discussion within the What in the World Matters? The Challenge of Spurring Innovation in Global Markets panel, which focused on the relatively slow uptake of biotech innovation in economies outside the US, and ...